Non-small Cell Lung Cance
Conditions
Interventions
A:Pemetrexed+cisplatin(2 cycles) followed by Alimta+cisplatin(2 cycles)+concurren thoracic irradiation
B:Paclitaxel+cisplatin(2 cycles) followed by Paclitaxel+cisplatin+concurrent thoracic irradiation
Sponsors
GuangZhou Istitute Of Respiratory Disease
Eligibility
Sex/Gender
All
Age
30 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients must have histologically or cytologically confirmed diagnosis of Non-small Cell Lung Cance with wild-type or has not detection of EGFR; 2. Histological confirmation of N2 nodal involvement was required in patients with mediastinal lymph node enlargement of less than 2 cm on computed tomography (CT) scans of the chest and upper abdomen or suspicious on whole body (18F)-fluorodeoxyglucose positron emission tomography (PET); 3. Patients were inoperable stage IIIA or stage IIIB disease locally advanced NSCLC; 4. Patients must have at least one measurable disease according to RECIST criteria and an Eastern Cooperative Oncology Group (ECOG) PS 0-1; 5. weight loss =1,500/mcL; platelet count >=100,000/mcL; hemoglobin >=9g/dl; 7. Laboratory measures required at study entry included bilirubin upper limit of normal (ULN); AST and ALT less than <=2.5 ULN; and alkaline phosphatase less than <=5ULN; 8. the patient must not have undergone prior chemotherapy or radiotherapy treatment; 9. No evidence of cancer in the past 5 years,beside carcinoma in situ of the cervix or breast and nonmelanoma skin cancer; 10. Patients can not accept other chemotherapy and radiotherapy, except patients dropped out of the test; 11. Patients must sign a study-specific informed consent form prior to study entry.
Exclusion criteria
Exclusion criteria: 1. Pregnant (positive pregnancy) or lactating women; 2. Women of childbearing potential and sexually active men enrolled in the study don't agree to practice effective contraception; 3. History of allergic reactions or sensitivity attributed to compounds of similar chemical or biologic composition to Alimta, Paclitaxel or cisplatin; 4. your doctor thinks would make you unable to participate; 5. ongoing or active infection; 6. Patients with other serious medical illnesses including, symptomatic congestive heart failure, poorly controlled cardiac arrhythmia, History of hemoptysis, that would limit compliance with study requirements; 7. History of significant neurological or mental disorder, including seizures or dementia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local control rate;Progress free survival;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life; | — |
Countries
China
Contacts
Public ContactJiexia Zhang
Outcome results
None listed